In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Xu Jian¹,Wang Bin¹,Fu Lei¹,Zhu Hui¹,Guo Shaochen¹,Huang Haihong²,Yin Dali²,Zhang Ye¹,Lu Yu¹

Affiliation:

1. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China

2. Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

Abstract

The riminophenazine agent clofazimine (CFZ) is repurposed as an important component of the new short-course multidrug-resistant tuberculosis regimen and significantly shortens first-line regimen for drug-susceptible tuberculosis in mice. However, CFZ use is hampered by its unwelcome skin discoloration in patients.

Funder

National Science and Technology Project of China

Global Alliance for TB Drug Development

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02155-18

Reference39 articles.

1. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies